Edition:
United Kingdom

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

37.05USD
3:51pm GMT
Change (% chg)

$0.11 (+0.30%)
Prev Close
$36.94
Open
$36.89
Day's High
$37.06
Day's Low
$36.73
Volume
956,378
Avg. Vol
5,240,800
52-wk High
$37.37
52-wk Low
$30.90

Chart for

About

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business... (more)

Overall

Beta: 0.99
Market Cap(Mil.): $214,682.30
Shares Outstanding(Mil.): 5,955.13
Dividend: 0.32
Yield (%): 3.55

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

Biotech M&A takes off as Sanofi and Celgene spend $20 billion

Biotech deal activity exploded on Monday with French drugmaker Sanofi and U.S.-based Celgene spending a combined total of more than $20 billion (14.39 billion pounds) to add new products for haemophilia and cancer to their medicine cabinets. | Video

4:23pm GMT

Biotech M&A takes off as Sanofi and Celgene spend $20 billion

Biotech deal activity exploded on Monday with French drugmaker Sanofi and U.S.-based Celgene spending a combined total of more than $20 billion to add new products for hemophilia and cancer to their medicine cabinets. | Video

4:09pm GMT

WRAPUP 2-Biotech M&A takes off as Sanofi and Celgene spend $20 billion

* Large drugmakers scour for products from smaller biotechs (Adds detail on gains in other biotech shares)

4:03pm GMT

Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion

PARIS French healthcare group Sanofi has agreed to buy U.S. haemophilia specialist Bioverativ for $11.6 billion(8.34 billion pounds), its biggest deal for seven years and a major play to strengthen its presence in treatments for rare diseases.

3:55pm GMT

Sanofi digs deep to buy U.S. hemophilia group Bioverativ for $11.6 billion

PARIS French healthcare group Sanofi has agreed to buy U.S. hemophilia specialist Bioverativ for $11.6 billion, its biggest deal for seven years and a major play to strengthen its presence in treatments for rare diseases. | Video

3:47pm GMT

UPDATE 5-Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 bln

* Shares in Sanofi down 4 percent (Updates shares, adds links to Breakingviews and other stories)

3:45pm GMT

Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion

PARIS French healthcare group Sanofi has agreed to buy U.S. haemophilia specialist Bioverativ for $11.6 billion, its biggest deal for seven years, which it said would strengthen its presence in treatments for rare diseases. | Video

1:21pm GMT

BRIEF-Kite Announces Clinical Collaboration With Pfizer

* KITE ANNOUNCES CLINICAL COLLABORATION TO EVALUATE INVESTIGATIONAL COMBINATION OF YESCARTA™ (AXICABTAGENE CILOLEUCEL) AND PFIZER’S UTOMILUMAB IN LARGE B-CELL LYMPHOMA

18 Jan 2018

BRIEF-Foundation Medicine, Pfizer Announce Partnership To Develop Companion Diagnostics For Pfizer’S Oncology Portfolio

* FOUNDATION MEDICINE AND PFIZER ANNOUNCE BROAD PARTNERSHIP TO DEVELOP COMPANION DIAGNOSTICS FOR PFIZER’S ONCOLOGY PORTFOLIO

16 Jan 2018

BRIEF-Novartis poaches Pfizer oncology head Elizabeth Barrett

* Elizabeth (Liz) Barrett, currently Global President Oncology at Pfizer, Inc., has been appointed CEO Novartis Oncology and a member of the Executive Committee of Novartis, effective February 1, 2018

11 Jan 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $147.10 -0.26
Novartis AG (NOVN.S) CHF83.30 -0.08
Merck & Co., Inc. (MRK.N) $61.37 +0.09
Roche Holding Ltd. (ROG.S) CHF235.80 +1.30
Roche Holding Ltd. (RO.S) CHF238.40 +0.60
Abbott Laboratories (ABT.N) $59.15 -0.16
Bayer AG (BAYGn.DE) €105.54 +1.46
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €69.89 -3.06
AstraZeneca plc (AZN.L) 5,055.00 +12.00

Earnings vs. Estimates